The table below shows HALOZYME THERAPEUTICS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$1.40B
$1.02B
$829.25M
$660.12M
$443.31M
$267.59M
Cost of revenue
$228.77M
$159.42M
$192.36M
$139.30M
$81.41M
$43.37M
Gross profit
-
-
-
-
-
-
R&D
-
$79.05M
$76.36M
$66.61M
$35.67M
$34.24M
SG&A
HALO annual revenue (10-K history)
HALOZYME THERAPEUTICS, INC. reported annual revenue of $1.40B for fiscal year 2025. That is up 37.6% from $1.02B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $146.69M (FY 2016) to $1.40B. Figures come from the company's audited annual reports as filed with the SEC.
